Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 19/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23718016 | 0.84 | HPGDS (0.42) | HPGDS | |
| SCHEMBL23815551 | 0.76 | HPGDS (0.40) | HPGDS | |
| SCHEMBL13537152 | 0.76 | KDM4E (0.40) | — | |
| SCHEMBL25049716 | 0.76 | HPGDS (0.49) | HPGDS | |
| SCHEMBL23682688 | 0.75 | HPGDS (0.48) | HPGDS | |
| SCHEMBL23815538 | 0.73 | NPC1 (0.40) | HPGDS | |
| SCHEMBL2625196 | 0.70 | MGAM (0.65) | HPGDS | |
| SCHEMBL23815698 | 0.70 | HPGDS (0.47) | HPGDS | |
| SCHEMBL23815584 | 0.69 | MEN1 (0.39) | — | |
| SCHEMBL23717893 | 0.68 | MEN1 (0.38) | HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | HPGDS 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.